- Home
- VVV vs GH Comparison
VVV vs GH Comparison
Compare VVV & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VVV
- GH
- Stock Information
- Founded
- VVV 1866
- GH 2011
- Country
- VVV United States
- GH United States
- Employees
- VVV N/A
- GH N/A
- Industry
- VVV Major Chemicals
- GH Medical Specialities
- Sector
- VVV Industrials
- GH Health Care
- Exchange
- VVV Nasdaq
- GH Nasdaq
- Market Cap
- VVV 5.5B
- GH 6.1B
- IPO Year
- VVV 2016
- GH 2018
- Fundamental
- Price
- VVV $36.45
- GH $42.87
- Analyst Decision
- VVV Buy
- GH Strong Buy
- Analyst Count
- VVV 10
- GH 18
- Target Price
- VVV $44.40
- GH $44.88
- AVG Volume (30 Days)
- VVV 1.9M
- GH 2.4M
- Earning Date
- VVV 02-06-2025
- GH 02-20-2025
- Dividend Yield
- VVV N/A
- GH N/A
- EPS Growth
- VVV N/A
- GH N/A
- EPS
- VVV 2.08
- GH N/A
- Revenue
- VVV $1,659,900,000.00
- GH $739,016,000.00
- Revenue This Year
- VVV $6.73
- GH $33.18
- Revenue Next Year
- VVV $12.21
- GH $16.41
- P/E Ratio
- VVV $17.35
- GH N/A
- Revenue Growth
- VVV 11.85
- GH 31.04
- 52 Week Low
- VVV $33.90
- GH $15.81
- 52 Week High
- VVV $48.27
- GH $50.89
- Technical
- Relative Strength Index (RSI)
- VVV 41.12
- GH 45.70
- Support Level
- VVV $37.53
- GH $47.03
- Resistance Level
- VVV $40.34
- GH $49.90
- Average True Range (ATR)
- VVV 1.12
- GH 2.62
- MACD
- VVV -0.20
- GH -0.60
- Stochastic Oscillator
- VVV 3.95
- GH 13.32
About VVV Valvoline Inc.
Valvoline Inc produces, markets, and sells automotive maintenance products, particularly lubricants, to retail outlets installers, and customers. The company offers various products such as engine oil, heavy-duty engine oil, motorcycle oil, grease and brake fluid, and others. Geographically, the majority of the revenue is generated from the United States of America.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.